Sci Rep:NONO-TFE3双融合FISH检测作为NONO-TFE3肾细胞癌诊断工具的适用性

2020-10-18 AlexYang MedSci原创

NONO-TFE3 RCC是Xp11.2易位肾细胞癌(RCC)的一种亚型。到目前为止,由于缺乏有效的诊断方法,仅有少量NONO-TFE3 RCC的报道。

NONO-TFE3 RCC是Xp11.2易位肾细胞癌(RCC)的一种亚型。到目前为止,由于缺乏有效的诊断方法,仅有少量NONO-TFE3 RCC的报道。

最近,有研究人员利用新型双融合荧光原位杂交(FISH)探针,发现了5例NONO-TFE3 RCC,并最终通过RT-PCR检测证实。组织病理学上来讲,5个病例均由片状上皮细胞和乳头状结构组成。细胞质丰富清晰,核仁不突出。此外,还鉴定了栅栏状细胞核、核下空泡和沙粒小体。最显著的特征是TFE3染色强阳性,但TFE3探针的分裂信号不明显,这可能导致Xp11.2易位RCC的误诊。5名患者的年龄中位数和肿瘤大小中位数分别为41.2岁和3.6cm。随访时间中位数为27个月,随访结果表明了NONO-TFE3 RCC患者具有中度的疾病进展和预后。

NONO-TFE3双融合FISH检测典型的阳性结果(a,b:男性;c,d:女性)

最后,研究人员指出,他们的研究阐述了NONO-TFE3双融合FISH探针诊断NONO-TFE3 RCC的有效性和可靠性。Xp11.2易位RCC的疑似病例在TFE3 FISH检测中表现出双相模式、TFE3染色强阳性和等效分裂信号,表明了患者患有NONO-TFE3 RCC的可能性。

原始出处:

Ning Liu, Wei Guo, Qiancheng Shi et al. The suitability of NONO-TFE3 dual-fusion FISH assay as a diagnostic tool for NONO-TFE3 renal cell carcinoma. Sci Rep. Oct 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1979032, encodeId=731119e903263, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 17 19:17:58 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951182, encodeId=455e1951182e8, content=<a href='/topic/show?id=a2c894e2694' target=_blank style='color:#2F92EE;'>#适用性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94726, encryptionId=a2c894e2694, topicName=适用性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Apr 21 08:17:58 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723639, encodeId=eff41e2363927, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Mon Nov 30 03:17:58 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525556, encodeId=c1dd1525556c1, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Tue Oct 20 06:17:58 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893112, encodeId=dc4c89311248, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Oct 19 18:24:56 CST 2020, time=2020-10-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1979032, encodeId=731119e903263, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 17 19:17:58 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951182, encodeId=455e1951182e8, content=<a href='/topic/show?id=a2c894e2694' target=_blank style='color:#2F92EE;'>#适用性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94726, encryptionId=a2c894e2694, topicName=适用性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Apr 21 08:17:58 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723639, encodeId=eff41e2363927, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Mon Nov 30 03:17:58 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525556, encodeId=c1dd1525556c1, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Tue Oct 20 06:17:58 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893112, encodeId=dc4c89311248, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Oct 19 18:24:56 CST 2020, time=2020-10-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1979032, encodeId=731119e903263, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 17 19:17:58 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951182, encodeId=455e1951182e8, content=<a href='/topic/show?id=a2c894e2694' target=_blank style='color:#2F92EE;'>#适用性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94726, encryptionId=a2c894e2694, topicName=适用性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Apr 21 08:17:58 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723639, encodeId=eff41e2363927, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Mon Nov 30 03:17:58 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525556, encodeId=c1dd1525556c1, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Tue Oct 20 06:17:58 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893112, encodeId=dc4c89311248, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Oct 19 18:24:56 CST 2020, time=2020-10-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1979032, encodeId=731119e903263, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 17 19:17:58 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951182, encodeId=455e1951182e8, content=<a href='/topic/show?id=a2c894e2694' target=_blank style='color:#2F92EE;'>#适用性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94726, encryptionId=a2c894e2694, topicName=适用性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Apr 21 08:17:58 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723639, encodeId=eff41e2363927, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Mon Nov 30 03:17:58 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525556, encodeId=c1dd1525556c1, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Tue Oct 20 06:17:58 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893112, encodeId=dc4c89311248, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Oct 19 18:24:56 CST 2020, time=2020-10-19, status=1, ipAttribution=)]
    2020-10-20 licz0427
  5. [GetPortalCommentsPageByObjectIdResponse(id=1979032, encodeId=731119e903263, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 17 19:17:58 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951182, encodeId=455e1951182e8, content=<a href='/topic/show?id=a2c894e2694' target=_blank style='color:#2F92EE;'>#适用性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94726, encryptionId=a2c894e2694, topicName=适用性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Apr 21 08:17:58 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723639, encodeId=eff41e2363927, content=<a href='/topic/show?id=7b08915917b' target=_blank style='color:#2F92EE;'>#诊断工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91591, encryptionId=7b08915917b, topicName=诊断工具)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c37033510464, createdName=surilei, createdTime=Mon Nov 30 03:17:58 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525556, encodeId=c1dd1525556c1, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Tue Oct 20 06:17:58 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893112, encodeId=dc4c89311248, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Mon Oct 19 18:24:56 CST 2020, time=2020-10-19, status=1, ipAttribution=)]
    2020-10-19 1244c0ebm28暂无昵称

    学习学习

    0

相关资讯

Oncogene:YB1/EphA2信号增强能够促进肾细胞癌获得性舒尼替尼耐药和转移潜能

VHL变异是肾透明细胞癌(ccRCC)中最常见的致瘤性病变,可导致HIF/VEGF通路的持续激活和不受控制的癌症进展。诸如舒尼替尼等受体酪氨酸激酶(RTK)抑制剂已被证明在转移性肾细胞癌(mRCC)中

盘点:近期肾细胞癌研究

肾细胞癌(简称肾癌)是泌尿系统中恶性程度较高的肿瘤,也是最常见的肿瘤之一,又称肾腺癌,占肾恶性肿瘤的80%~90%。据调查,肾细胞癌在我国泌尿生殖系统肿瘤中占第二位,仅次于膀胱肿瘤,占成人恶性肿瘤的2

Br J Cancer:CRISPR/Cas9全基因组功能丧失筛选技术鉴定法尼基蛋白转移酶参与肾细胞癌的舒尼替尼耐药性

肾细胞癌(RCC)作为最常见的肾癌,近年来发病率在不断的上升,RCC有多种亚型,其中透明肾细胞癌(ccRCC)约占所有RCC肿瘤的85%。

Oncogene:雄激素受体以氧依赖性方式调控VHL野生型透明细胞肾细胞癌的转移途径

最近的研究表明,雄激素受体(AR)在调控VHL突变型透明细胞肾细胞癌(ccRCC)的转移中具有重要作用。然而,AR在VHL野生型(VHL-wt)ccRCC中作用的确切机制仍不清楚。

Oncogene:ApoC1能够促进透明细胞肾细胞癌的转移

透明细胞肾细胞癌(ccRCC)是最常见的肾癌,且诊断经常为晚期。即使经过适当的治疗,也容易发生不可预测的转移。抗血管生成治疗是转移性ccRCC最有效的治疗方法。因此,探索抑制血管生成和转移的新方法有可

Eur Urol:转移肾细胞癌患者的粪便微生物组分析

预临床模型和早期临床数据表明肠道微生物组与的实体肿瘤的免疫治疗响应之间存在相互作用,其中包括了转移性肾细胞癌(mRCC)。